Menest Articles
JAMA Study Casts Doubt On Estrogen Role In Alzheimer's
16 March 1998
Product News In Brief
12 March 1998
Duramed To File For Conjugated Estrogens
26 February 1998
US Court Rules For Solvay In Sage Suit Over Menogen
4 February 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
Drug Cos Must Act Now To Ensure Future Prosperity
22 January 1998
New Products In 1998; A Look Ahead
6 January 1998
FDA Approves Raloxifene For Osteoporosis
11 December 1997
Solvay Files Estratab For Osteoporosis
11 December 1997
Zeneca Allays Fears Of Near-Term Product Gap
4 December 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
Duramed Takes New Tack In Premarin Bid
7 August 1997
Barr Labs Launches First Generic Warfarin In USA
31 July 1997
Duramed Takes On FDA Over Generic Premarin Block
31 July 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
Duramed Files Premarin Appeal
19 June 1997
New York Stock Comment
12 May 1997
FDA Rejects Generic Premarin Challenge
12 May 1997
Barr & Wyeth Ayerst's Premarin Battle
25 November 1996
Major US Drug Cos Post Strong Results In 3rd Qtr
28 October 1996
New Understanding Of Estrogen Benefit For Women: Lilly
9 September 1996
Single-Digit Profits Growth For B-MS And W-L
5 August 1996
Generic Premarin
20 May 1996
Strong Growth At AHP At Start Of 1996
6 May 1996
New Turn In Generic Premarin Dispute
29 April 1996
World Markets: Cancer, Cardiovascular, Menopause
19 February 1996
Sandoz Launches Nasal Calcitonin In USA
18 December 1995
Duramed 3rd quarter results
27 November 1995
Duramed Move In Premarin Fracas
16 October 1995
US OK For Miacalcin
4 September 1995
FDA Panel Verdict On Premarin Inconclusive
7 August 1995
FDA Hearing To Determine Generic Premarin Fate
31 July 1995
Strong International Sales For US Cos In 2nd Qtr
31 July 1995
Merck's Fosamax Nears Market In USA
24 July 1995
Wyeth Acts To Protect Premarin Business
5 June 1995
Upjohn suing AHP for infringment on Provera
22 May 1995
Sanofi Launches New HRT Approach In UK
8 May 1995
Swedish Pharmaceutical Trade In 1994
13 March 1995
Zeneca Gets First Approval For Casodex
6 March 1995
IMS Studies US Retail Drug Payments
16 January 1995
Prempro Approved In USA
9 January 1995
Solid 3rd Qtr Growth For Large Pharma Cos
31 October 1994
USA's Top-Selling Drugs In 1993
24 October 1994
Euro Epidemiology TrendsTo Year 2010; Cancer
17 October 1994
AHP Bid For Cyanamid Will Broaden Product Range
15 August 1994
Strong Gains By US Firms In 2nd Quarter
1 August 1994
RECORD RESULTS FOR AMERICAN HOME
25 April 1994
PREVENTION PRIORITIES FOR OSTEOPOROSIS
28 March 1994
EVENING PRIMROSE OIL AND THE MENOPAUSE
28 February 1994
ESTROGEN AND ALZHEIMER'S
21 February 1994
STRONG DOLLAR WEAKENS US 1993 RESULTS
31 January 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
RAPID GROWTH FOR WORLD ENDOCRINEs
25 October 1993
R&D INVESTMENTS BY US GENERICS MAKERS
28 June 1993
ELI LILLY'S RALOXIFENE: PHASE II RESULTS
26 April 1993
ZENECA REPORTS ANTICANCER SUCCESSES
19 April 1993
US/CANADA DRUG PRICE STUDY "MISLEADING"
2 November 1992
ANTI-ESTROGENS FOR MELANOMA?
7 September 1992
US FDA ABANDONS COMPANY ALERT LIST
29 June 1992
WYETH LOSES ROUND IN GENERICS BATTLE
15 June 1992
HORMONE REPLACEMENT THERAPY: US REPORT
8 June 1992
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
